Rajani Jagana

Professor

Last publication 2025 Last refreshed 2026-05-09

faculty

Internal Med, College of Medicine

7 h-index 41 pubs 118 cited

Biography and Research Information

OverviewAI-generated summary

Rajani Jagana's research primarily investigates pulmonary arterial hypertension, with a specific focus on the influence of iron deficiency on clinical and hemodynamic parameters within these patient cohorts. Her work also extends to critical care, examining the association between tocilizumab and an increased risk of fungal infections in critically ill patients with COVID-19 and acute renal failure. Jagana has contributed to case reports detailing rare presentations of pulmonary emboli and adverse reactions to medications like hydroxychloroquine. Additionally, her research has explored the efficiency of personal protective equipment in healthcare emergencies. Jagana holds an h-index of 7, with 40 total publications and 117 citations. She has collaborated with several researchers from the University of Arkansas for Medical Sciences, including Nikhil Meena, MOHAMMAD KHRAIS, and Arjun Rao, with whom she shares multiple publications.

Metrics

  • h-index: 7
  • Publications: 41
  • Citations: 118

Selected Publications

  • Successful Management of ETI-Induced-Urticaria (2025)
    1 citation DOI OpenAlex
  • A Case of Hydroxychloroquine Associated Catatonia in SLE (2025)
    1 citation DOI OpenAlex
  • Reduction of Methicillin-resistant Staphylococcus Aureus (MRSA) Acquisition in Patients With Cystic Fibrosis: Single-center Quality Improvement Project (2025)
  • Idiopathic Hypereosinophilic Syndrome in a Rare Case of Quadricuspid Aortic Valve (2024)
  • Tocilizumab Is Associated with Increased Risk of Fungal Infections among Critically Ill Patients with COVID-19 and Acute Renal Failure: An Observational Cohort Study (2023)
    8 citations DOI OpenAlex
  • A Rare Case of Pulmonary Emboli Presenting With ST Elevation on ECG (2022)
    2 citations DOI OpenAlex
  • Personal Protective Equipment Efficiency in Healthcare Emergencies: A Single-Center Experience (2022)
    1 citation DOI OpenAlex
  • Tocilizumab is Associated with Increased Risk of Fungal Infections Among Critically Ill Patients with COVID-19 and Acute Renal Failure: An Observational Cohort Study. (2021)
    5 citations DOI OpenAlex
  • Tocilizumab Is Associated with Increased Risk of Fungal Infections Among Critically Ill Patients with COVID-19 (2021)
    3 citations DOI OpenAlex

View all publications on OpenAlex →

Research Interests

1. Cystic Fibrosis: I have done and been doing many research projects in field of cystic fibrosis in collaboration with Cystic Fibrosis Foundation. These international and multicenter center studies have made an impact in the lives of cystic fibrosis patients by increasing their estimated life survival and decreased hospitalizations. I am principal investigator of few ongoing multicenter studies and sub-investigator of multiple studies at our center in the field of Cystic fibrosis and non CF bronchiectasis. 2. COVID-19: I am sub-investigator of multiple COVID-19 studies currently undergoing in our Institution. 3. I involve students, residents and fellows in research projects and may of these projects and case reports have been presented in national and international pulmonary and critical care conferences 4. I have authored 7 manuscripts, which have been published in peer- reviewed international medical journals. In addition, I have made over 26 posters and presentations that have been showcased at the international conferences including American Thoracic Society, American college of physicians (ACP), society of critical care medicine (SCCM) and CHEST conferences.

Grants & Funding

  • LEAPP CF: Leadership and Education Advanced Practice Provider Fellow Program in CF 2023 Cystic Fibrosis Foundation Principal Investigator
  • No FP attached Savara, Inc Principal Investigator
  • No FP attached Savara, Inc Principal Investigator
  • CFF Care Center Award 2021_2022 Cystic Fibrosis Foundation Co-Investigator
  • A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis (IRB 298318) Arcturus Therapeutics, Inc. - Pass Through: Worldwide Clinical Trials, Inc Principal Investigator
  • Cystic Fibrosis Care Centers -2020-2021 Continuation - Continuation - Continuation Cystic Fibrosis Foundation Co-Investigator

Collaboration Network

41 Collaborators 3 Institutions 1 Country

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics